The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
about
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effectsElevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumorsTumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cellsProstate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine DesignHLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor ImmunotherapyImpaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy.Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cellsA soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulationDifferential geometric analysis of alterations in MH α-helicesBioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations.
P2860
Q33707475-390FC2C4-BD1C-4A10-806F-DA8674DAA53FQ33860104-096210AE-D254-4BB6-867D-1FB6ADD9AAD1Q34155000-9F474E1F-C631-48FB-84C8-2E93F0499E52Q34161849-3FB22A53-11B4-4FF8-BECA-07A2DC72D1BEQ34259644-66A6A6B7-F567-459B-B007-4D2A4A0F8271Q35014206-73C64C8A-2DAA-4B76-8194-1168E461E4ABQ35071179-5C51B48D-4B6D-4227-8C19-3D4FBCA6302EQ36039709-490319FC-5223-4441-8E31-23C2E8E2AF8AQ36386903-DE83B7AA-824E-4377-B429-A1D84BEE7E28Q36478578-4C1EE960-B7C7-4495-9E66-AD31746F807CQ36487242-80F2D698-0FAA-4D07-8277-44DE7BB11617Q37252253-761D2552-6079-4076-B19E-60447DF0C0B0Q37773238-B8DCDA13-3E2D-48CD-861E-2B1867C2C0ACQ38060734-97162813-35C1-471D-85AC-480078749CF1Q38365107-6B161E76-F6B0-493B-8C4B-A38386EB487FQ39114787-01F2C52F-2B9F-413A-8F27-53C1C618208FQ39832869-F3C73BA2-5726-4366-B1CE-78DEB92655F2Q42114592-5DE06739-D07E-4303-A5EE-1E4733917B1AQ42232179-132A4A74-8507-4155-9356-2B1477FBBB78Q42549284-B9707127-375A-43B0-850C-B1D49BB38146Q49232945-AE4473A1-DF16-4DED-9098-7F03C5B13603
P2860
The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The absence of invariant chain ...... ive type 1 CD4+ T lymphocytes.
@en
type
label
The absence of invariant chain ...... ive type 1 CD4+ T lymphocytes.
@en
prefLabel
The absence of invariant chain ...... ive type 1 CD4+ T lymphocytes.
@en
P2093
P2860
P1476
The absence of invariant chain ...... tive type 1 CD4+ T lymphocytes
@en
P2093
Bruce R Ksander
James A Thompson
Minu K Srivastava
Suzanne Ostrand-Rosenberg
Virginia K Clements
P2860
P2888
P304
P356
10.1007/S00262-007-0381-5
P577
2007-08-28T00:00:00Z
P5875
P6179
1024270781